KLF BIOLOGY IN ORGANS OF METABOLIC INTEREST
HEART. The heart is a major regulator of systemic metabolism; it consumes a large amount of lipids and glucose to produce the 5 to 6 kg of adenosine triphosphate (ATP) that is needed for pumping approximately 7,000 l of blood per day. To meet this energetic demand, the heart relies primarily on fatty acid (FA) b-oxidation, which supplies approximately 70% of the heart's ATP (52) . Therefore, a robust regulatory network is in place to coordinate cardiac and systemic metabolism. Mitochondrial biogenesis is regulated in large part by the coactivator peroxisome proliferator-activated receptor (PPAR)g coactivator 1 (PGC-1), which interacts with nuclear receptors, including estrogen-related receptor, PPARa, and nuclear respiratory factor, to regulate genes critical to mitochondrial function (55) . KLF4 forms a transcriptional complex with estrogen-related receptor and PGC-1, in which KLF4 is required for optimal activity of the estrogenrelated receptor-PGC-1 complex (56) . Concordantly, cardiac-specific Klf4 -/-mice develop heart dysfunction with aging or pressure overload associated with 
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Klf2
-/-Lethal E12.5-14.5, defective blood vessel, severe bleeding (218) Splenic and lymph node T cells, abnormal cell surface phenotype (219) Embryonic globin genes expression affected but not adult globin genes (144) Splenomegaly, increased splenic B-cell subsets (220) Altered B-cell tissue distribution and expression of trafficking molecules (221) Endothelial-Klf2
-/-Cardiac failure, vascular abnormalities (222) Cerebral cavernous malformations, vascular lesions, enlarged capillaries, irregular structure (223) Glomerular endothelial cell injury, diabetic nephropathy (215) Hematopoietic Klf2
-/-
Restriction of chemokine receptor expression patterns, regulation of T-cell migration (224) T-cell-Klf2
-/-Unrestrained cytokine production, bystander chemokine receptor upregulation (225) Fetal liver Klf2 -/-chimeras Regulation of thymocyte and T-cell migration (226)
Reduced adipocyte size and less white adipose tissue (87) Resistance to diet-induced obesity and glucose intolerance, increased adipolin (90) 
KLF15 Klf15
-/-Fasting hypoglycemia, reduced expression of hepatic and skeletal muscle catabolism genes, loss of circadian expression of hepatic metabolism genes, loss of bile acid synthetic enzymes (67, 114, 119, 197) Protection against hepatic insulin resistance and fatty liver under high-fat feeding (196) Fatigue after endurance exercise, reduced skeletal muscle fatty acid oxidation gene expression (66) Cardiac lipid oxidation deficit, susceptibility to pressure overload-induced cardiac hypertrophy (60, 155) Adipose-KLF15 Tg Insulin resistance and protection from weight gain, improved glucose tolerance due to increased insulin synthesis by pancreas (171) is a critical component of the PGC-1-PPAR complex in skeletal muscle, as has previously been described in the heart (61).
Insulin-dependent glucose uptake, which is important for type 2 muscle fibers, results from translocation of preformed glucose transporter type 4 (GLUT4)-containing vesicles to the cell membrane.
Upon insulin stimulation, these vesicles fuse with the plasma membrane, and GLUT4 transporters are In the fasted state, circulating levels of alanine are increased, resulting from catabolism of branched chain amino acids (BCAAs) in the skeletal muscle.
Circulating alanine can be converted to pyruvate and Pollak et al.
used for gluconeogenesis in the liver (70, 71 Pollak et al. in causing adipose-specific changes in mice remains to be investigated, and a definite pro-adipogenic role for this family member has yet to be proven.
In WAT, KLF2 (78), KLF3 (87), and KLF7 (88) Due to the high metabolic activity of BAT, browning of WAT has been suggested as a therapeutic intervention for obesity in humans aiming to consume stored FAs by converting them to heat (96) . KLF11 (97) and KLF15 (98) Hepatic glucose metabolism plays a crucial role in maintaining normal concentrations of blood glucose.
During food deprivation, when insulin levels are low and glucagon levels are high, the liver provides glucose, both by gluconeogenesis and glycogen breakdown. Gluconeogenesis is one of the most
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various tissues (109 Pollak et al. 
ROLE OF KLFs IN DISEASES THAT ARE ASSOCIATED WITH METABOLIC ABNORMALITIES
HEART FAILURE. Heart failure is a clinical syndrome in which the heart is unable to effectively pump enough blood to meet the metabolic requirements of the organism. As the end stage of many diseases of the cardiovascular system, including acute coronary syndrome, various cardiomyopathies, and hypertension, the prevalence of heart failure has been increasing in the developing world as a result of the aging population and increased survival after myocardial infarction (145) . Therefore, strategies aimed at the primary prevention of heart failure, as well as management of existing heart failure, are highly sought.
Metabolic dysfunction is a characteristic of advanced heart failure that occurs due to ischemia, pathological hypertrophy, and various forms of dilated cardiomyopathy (55, (146) (147) (148) . These defects include reduced capacity for respiration, reduced FA oxidation, and increased carbohydrate oxidation.
Modulation of cardiac FA oxidation has been proposed as a potential therapeutic strategy to improve cardiac function in patients with heart failure.
Changes in metabolic function and substrate use likely contribute to cardiac disease progression as evidenced by animal models of cardiac disease (58). regulates the catabolism of BCAAs, which is postulated to protect against pressure overload-induced heart failure (156) and ischemia-reperfusion injury (157) . Mechanistically, elevated levels of BCAAs inhibit glucose metabolism by suppressing glucose uptake and inhibiting mitochondrial respiration (156, 157) . Importantly, KLF15 is a key inducer of BCAA catabolic genes, including BCAT, the BCKD complex subunits, and PP2Cm, which are reduced in KLF15 knockout hearts (156) . Taken together, these observations suggest that reduced KLF15 may not only be involved in the fetal metabolic profile of failing hearts but also in BCAA catabolic deficiency, which contributes to mitochondrial dysfunction. Therefore, restoring expression of KLF15 in heart failure may be the target of future therapies designed to manage cardiac function in advanced heart failure.
KLF6 exacerbates cardiac fibrosis as demonstrated by reduced fibrosis and preserved cardiac function in
Klf6 þ/-mice after angiotensin II infusion (158) . This outcome seems to result from cardiomyocyte KLF6 because cardiomyocyte-specific, but not fibroblast-specific, Klf6 -/-mice display the same protection from fibrosis. Cardiomyocyte KLF6 is induced in cardiomyocytes early after angiotensin stimulation and suppresses expression of thrombospondin 4,
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Pollak et al. In mouse models of obesity, hepatic KLF11 is decreased (111) . In Klf11 -/-mice fed a normal diet, body weight and energy expenditure are not affected.
However, loss of Klf11 provides a protective effect against high-fat DIO and hypercholesterolemia, and also results in an increased metabolic rate in female
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Pollak et al. silencing ameliorates hepatosteatosis in ob/ob mice.
Because PPARg promotes hepatic steatosis (192, 193) , the KLF2-driven mechanism that mediates hepatic lipid accumulation must be different from the adipose tissue, where KLF2 inhibits PPARg expression (77) . The mechanism for hepatic lipid accumulation may, at least in part, derive from KLF2 induction of cluster of differentiation 36 (CD36), a membrane protein that facilitates FA uptake (185, 194) . The KLF2-mediated hepatosteatosis development is severely diminished in cluster of differentiation 36-deficient mice (185) .
Although KLF2 has opposite roles in the liver and the adipose tissue, KLF5 seems to have similar effects in both organs. Hepatic KLF5 is a positive regulator of Pparg2 expression and genes involved in FA uptake and TG synthesis (186) , and it promotes hepatic lipid accumulation. The regulation of KLF5 activity in the liver is controlled by a ubiquitin-dependent degradation mechanism that is mediated by F box and WD repeat domain containing 7 (FBW7).
Adenovirus-mediated knockdown of hepatic Fbw7
results in hepatosteatosis due to reduced KLF5 degradation, and increased expression of Pparg2 and genes involved in FA uptake and TG synthesis.
Pollak et al. plasma TG levels (112) . Inhibition of KLF15 is protective against high-fat-diet-induced hepatic steatosis via increased expression of FA oxidation genes (196) .
Metformin, which inhibits hepatic gluconeogenesis and is a pharmacological agent for type 2 diabetes mellitus (T2DM), promotes degradation of KLF15
protein (197) and alleviates hepatic steatosis (198) . Pollak et al. are associated with MODY7 and human neonatal diabetes mellitus (124, 204) . The Q62R mutation is a restoration. Klf15 -/-mice are protected from hepatic insulin resistance induced by a high-fat diet (196) .
Although metformin administration has been shown to improve hepatic steatosis (198) , the contribution of metformin-induced KLF15 degradation on hepatic insulin sensitivity has not been evaluated. is inhibited in the muscle of mice fed a high-fat diet and in db/db mice, which is a model of T2DM (115) . 
